FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098640714> ?p ?o ?g. }

• W2098640714 endingPage "978" @default.
• W2098640714 startingPage "962" @default.
• W2098640714 abstract "Chromosomal translocations generating oncogenic transcription factors are the hallmark of a variety of tumors, including many sarcomas. Ewing sarcoma family of tumors (ESFTs) are characterized by the t(11;22)(q24;q12) translocation that generates the Ewing sarcoma breakpoint region 1 and Friend leukemia virus integration 1 (EWS-FLI1) fusion transcription factor responsible for the highly malignant phenotype of this tumor. Although continued expression of EWS-FLI1 is believed to be critical for ESFT cell survival, a clinically effective small-molecule inhibitor remains elusive likely because EWS-FLI1 is a transcription factor and therefore widely felt to be undruggable.We developed a high-throughput screen to evaluate more than 50 000 compounds for inhibition of EWS-FLI1 activity in TC32 ESFT cells. We used a TC32 cell-based luciferase reporter screen using the EWS-FLI1 downstream target NR0B1 promoter and a gene signature secondary screen to sort and prioritize the compounds. We characterized the lead compound, mithramycin, based on its ability to inhibit EWS-FLI1 activity in vitro using microarray expression profiling, quantitative reverse transcription-polymerase chain reaction, and immunoblot analysis, and in vivo using immunohistochemistry. We studied the impact of this inhibition on cell viability in vitro and on tumor growth in ESFT xenograft models in vivo (n = 15-20 mice per group). All statistical tests were two-sided.Mithramycin inhibited expression of EWS-FLI1 downstream targets at the mRNA and protein levels and decreased the growth of ESFT cells at half maximal inhibitory concentrations between 10 (95% confidence interval [CI] = 8 to 13 nM) and 15 nM (95% CI = 13 to 19 nM). Mithramycin suppressed the growth of two different ESFT xenograft tumors and prolonged the survival of ESFT xenograft-bearing mice by causing a decrease in mean tumor volume. For example, in the TC32 xenograft model, on day 15 of treatment, the mean tumor volume for the mithramycin-treated mice was approximately 3% of the tumor volume observed in the control mice (mithramycin vs control: 69 vs 2388 mm(3), difference = 2319 mm(3), 95% CI = 1766 to 2872 mm(3), P < .001).Mithramycin inhibits EWS-FLI1 activity and demonstrates ESFT antitumor activity both in vitro and in vivo." @default.
• W2098640714 created "2016-06-24" @default.
• W2098640714 creator A5005450827 @default.
• W2098640714 creator A5017638182 @default.
• W2098640714 creator A5024222743 @default.
• W2098640714 creator A5028721392 @default.
• W2098640714 creator A5031571077 @default.
• W2098640714 creator A5052792022 @default.
• W2098640714 creator A5066348866 @default.
• W2098640714 creator A5066585382 @default.
• W2098640714 creator A5067388546 @default.
• W2098640714 creator A5082248977 @default.
• W2098640714 creator A5084422528 @default.
• W2098640714 creator A5090491672 @default.
• W2098640714 date "2011-06-08" @default.
• W2098640714 modified "2023-10-11" @default.
• W2098640714 title "Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening" @default.
• W2098640714 cites W1546952499 @default.
• W2098640714 cites W1903528106 @default.
• W2098640714 cites W1909732837 @default.
• W2098640714 cites W192608075 @default.
• W2098640714 cites W1968503492 @default.
• W2098640714 cites W1971146179 @default.
• W2098640714 cites W1973195150 @default.
• W2098640714 cites W1976475446 @default.
• W2098640714 cites W1977662716 @default.
• W2098640714 cites W1979061844 @default.
• W2098640714 cites W1983395480 @default.
• W2098640714 cites W1988944307 @default.
• W2098640714 cites W1991001144 @default.
• W2098640714 cites W1993816996 @default.
• W2098640714 cites W1997220932 @default.
• W2098640714 cites W2000721637 @default.
• W2098640714 cites W2007438323 @default.
• W2098640714 cites W2010078128 @default.
• W2098640714 cites W2011945942 @default.
• W2098640714 cites W2020583412 @default.
• W2098640714 cites W2022352188 @default.
• W2098640714 cites W2024423624 @default.
• W2098640714 cites W2025739622 @default.
• W2098640714 cites W2025989401 @default.
• W2098640714 cites W2027630134 @default.
• W2098640714 cites W2027739413 @default.
• W2098640714 cites W2035259022 @default.
• W2098640714 cites W2036463815 @default.
• W2098640714 cites W2042056286 @default.
• W2098640714 cites W2042155367 @default.
• W2098640714 cites W2044379241 @default.
• W2098640714 cites W2045489734 @default.
• W2098640714 cites W2054171696 @default.
• W2098640714 cites W2055213294 @default.
• W2098640714 cites W2060139401 @default.
• W2098640714 cites W2061054148 @default.
• W2098640714 cites W2068589834 @default.
• W2098640714 cites W2068923084 @default.
• W2098640714 cites W2069351898 @default.
• W2098640714 cites W2082138815 @default.
• W2098640714 cites W2083009197 @default.
• W2098640714 cites W2085501747 @default.
• W2098640714 cites W2092230690 @default.
• W2098640714 cites W2101854267 @default.
• W2098640714 cites W2102249538 @default.
• W2098640714 cites W2107078868 @default.
• W2098640714 cites W2108244474 @default.
• W2098640714 cites W2111042503 @default.
• W2098640714 cites W2113855026 @default.
• W2098640714 cites W2116634113 @default.
• W2098640714 cites W2123302336 @default.
• W2098640714 cites W2130410032 @default.
• W2098640714 cites W2130556692 @default.
• W2098640714 cites W2132983193 @default.
• W2098640714 cites W2142878985 @default.
• W2098640714 cites W2147887118 @default.
• W2098640714 cites W2151891881 @default.
• W2098640714 cites W2156695950 @default.
• W2098640714 cites W2159973719 @default.
• W2098640714 cites W2161444433 @default.
• W2098640714 cites W2163374376 @default.
• W2098640714 cites W2170407716 @default.
• W2098640714 cites W2171302499 @default.
• W2098640714 cites W2317345315 @default.
• W2098640714 cites W2319655436 @default.
• W2098640714 cites W2326722293 @default.
• W2098640714 cites W4256069758 @default.
• W2098640714 doi "https://doi.org/10.1093/jnci/djr156" @default.
• W2098640714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3119649" @default.
• W2098640714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21653923" @default.
• W2098640714 hasPublicationYear "2011" @default.
• W2098640714 type Work @default.
• W2098640714 sameAs 2098640714 @default.
• W2098640714 citedByCount "173" @default.
• W2098640714 countsByYear W20986407142012 @default.
• W2098640714 countsByYear W20986407142013 @default.
• W2098640714 countsByYear W20986407142014 @default.
• W2098640714 countsByYear W20986407142015 @default.
• W2098640714 countsByYear W20986407142016 @default.
• W2098640714 countsByYear W20986407142017 @default.
• W2098640714 countsByYear W20986407142018 @default.

• next